Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol

Research output: Contribution to journalJournal article – Annual report year: 2017Researchpeer-review

Standard

Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. / Wolthers, B. O.; Frandsen, Thomas L.; Abrahamsson, Jonas; Albertsen, B. K.; Helt, L. R.; Heyman, Mats; Jonsson, Olafur G.; Korgvee, L. T.; Lund, B.; Raja, R. A.; Rasmussen, K. K.; Taskinen, M.; Tulstrup, M.; Vaitkeviciene, G. E.; Yadav, Rachita; Gupta, R.; Schmiegelow, K.

In: Leukemia, Vol. 31, No. 2, 2016, p. 325-332.

Research output: Contribution to journalJournal article – Annual report year: 2017Researchpeer-review

Harvard

Wolthers, BO, Frandsen, TL, Abrahamsson, J, Albertsen, BK, Helt, LR, Heyman, M, Jonsson, OG, Korgvee, LT, Lund, B, Raja, RA, Rasmussen, KK, Taskinen, M, Tulstrup, M, Vaitkeviciene, GE, Yadav, R, Gupta, R & Schmiegelow, K 2016, 'Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol', Leukemia, vol. 31, no. 2, pp. 325-332. https://doi.org/10.1038/leu.2016.203

APA

Wolthers, B. O., Frandsen, T. L., Abrahamsson, J., Albertsen, B. K., Helt, L. R., Heyman, M., ... Schmiegelow, K. (2016). Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. Leukemia, 31(2), 325-332. https://doi.org/10.1038/leu.2016.203

CBE

Wolthers BO, Frandsen TL, Abrahamsson J, Albertsen BK, Helt LR, Heyman M, Jonsson OG, Korgvee LT, Lund B, Raja RA, Rasmussen KK, Taskinen M, Tulstrup M, Vaitkeviciene GE, Yadav R, Gupta R, Schmiegelow K. 2016. Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. Leukemia. 31(2):325-332. https://doi.org/10.1038/leu.2016.203

MLA

Vancouver

Wolthers BO, Frandsen TL, Abrahamsson J, Albertsen BK, Helt LR, Heyman M et al. Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. Leukemia. 2016;31(2):325-332. https://doi.org/10.1038/leu.2016.203

Author

Wolthers, B. O. ; Frandsen, Thomas L. ; Abrahamsson, Jonas ; Albertsen, B. K. ; Helt, L. R. ; Heyman, Mats ; Jonsson, Olafur G. ; Korgvee, L. T. ; Lund, B. ; Raja, R. A. ; Rasmussen, K. K. ; Taskinen, M. ; Tulstrup, M. ; Vaitkeviciene, G. E. ; Yadav, Rachita ; Gupta, R. ; Schmiegelow, K. / Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. In: Leukemia. 2016 ; Vol. 31, No. 2. pp. 325-332.

Bibtex

@article{b0f296bd56d5457da0687029b77a590b,
title = "Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol",
abstract = "Asparaginase (ASP)-associated pancreatitis (AAP) occurs during acute lymphoblastic leukemia treatment. Among 1285 children (1.0-17.9 years) diagnosed during July 2008-December 2014 and treated according to the Nordic/Baltic ALL2008 protocol, 86 (cumulative incidence = 6.8{\%}) developed AAP. Seventy-three cases were severe (diagnostic AAP criteria persisting 472 h) and 13 mild. Cases were older than controls (median: 6.5 vs 4.5 years; P = 0.001). Pseudocysts developed in 28{\%}. Of the 20 re-exposed to ASP, 9 (45{\%}) developed a second AAP. After a median follow-up of 2.3 years, 8{\%} needed permanent insulin therapy, and 7{\%} had recurrent abdominal pain. Germline DNA on 62 cases and 638 controls was genotyped on Omni2.5exome-8-v1.2 BeadChip arrays. Overall, the ULK2 variant rs281366 showed the strongest association with AAP (P = 5.8x10(-7); odds ratio (OR) = 6.7). Cases with the rs281366 variant were younger (4.3 vs 8 years; P = 0.015) and had lower risk of AAP-related complications (15{\%} vs 43{\%}; P = 0.13) compared with cases without this variant. Among 45 cases and 517 controls",
author = "Wolthers, {B. O.} and Frandsen, {Thomas L.} and Jonas Abrahamsson and Albertsen, {B. K.} and Helt, {L. R.} and Mats Heyman and Jonsson, {Olafur G.} and Korgvee, {L. T.} and B. Lund and Raja, {R. A.} and Rasmussen, {K. K.} and M. Taskinen and M. Tulstrup and Vaitkeviciene, {G. E.} and Rachita Yadav and R. Gupta and K. Schmiegelow",
year = "2016",
doi = "10.1038/leu.2016.203",
language = "English",
volume = "31",
pages = "325--332",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

RIS

TY - JOUR

T1 - Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol

AU - Wolthers, B. O.

AU - Frandsen, Thomas L.

AU - Abrahamsson, Jonas

AU - Albertsen, B. K.

AU - Helt, L. R.

AU - Heyman, Mats

AU - Jonsson, Olafur G.

AU - Korgvee, L. T.

AU - Lund, B.

AU - Raja, R. A.

AU - Rasmussen, K. K.

AU - Taskinen, M.

AU - Tulstrup, M.

AU - Vaitkeviciene, G. E.

AU - Yadav, Rachita

AU - Gupta, R.

AU - Schmiegelow, K.

PY - 2016

Y1 - 2016

N2 - Asparaginase (ASP)-associated pancreatitis (AAP) occurs during acute lymphoblastic leukemia treatment. Among 1285 children (1.0-17.9 years) diagnosed during July 2008-December 2014 and treated according to the Nordic/Baltic ALL2008 protocol, 86 (cumulative incidence = 6.8%) developed AAP. Seventy-three cases were severe (diagnostic AAP criteria persisting 472 h) and 13 mild. Cases were older than controls (median: 6.5 vs 4.5 years; P = 0.001). Pseudocysts developed in 28%. Of the 20 re-exposed to ASP, 9 (45%) developed a second AAP. After a median follow-up of 2.3 years, 8% needed permanent insulin therapy, and 7% had recurrent abdominal pain. Germline DNA on 62 cases and 638 controls was genotyped on Omni2.5exome-8-v1.2 BeadChip arrays. Overall, the ULK2 variant rs281366 showed the strongest association with AAP (P = 5.8x10(-7); odds ratio (OR) = 6.7). Cases with the rs281366 variant were younger (4.3 vs 8 years; P = 0.015) and had lower risk of AAP-related complications (15% vs 43%; P = 0.13) compared with cases without this variant. Among 45 cases and 517 controls

AB - Asparaginase (ASP)-associated pancreatitis (AAP) occurs during acute lymphoblastic leukemia treatment. Among 1285 children (1.0-17.9 years) diagnosed during July 2008-December 2014 and treated according to the Nordic/Baltic ALL2008 protocol, 86 (cumulative incidence = 6.8%) developed AAP. Seventy-three cases were severe (diagnostic AAP criteria persisting 472 h) and 13 mild. Cases were older than controls (median: 6.5 vs 4.5 years; P = 0.001). Pseudocysts developed in 28%. Of the 20 re-exposed to ASP, 9 (45%) developed a second AAP. After a median follow-up of 2.3 years, 8% needed permanent insulin therapy, and 7% had recurrent abdominal pain. Germline DNA on 62 cases and 638 controls was genotyped on Omni2.5exome-8-v1.2 BeadChip arrays. Overall, the ULK2 variant rs281366 showed the strongest association with AAP (P = 5.8x10(-7); odds ratio (OR) = 6.7). Cases with the rs281366 variant were younger (4.3 vs 8 years; P = 0.015) and had lower risk of AAP-related complications (15% vs 43%; P = 0.13) compared with cases without this variant. Among 45 cases and 517 controls

U2 - 10.1038/leu.2016.203

DO - 10.1038/leu.2016.203

M3 - Journal article

VL - 31

SP - 325

EP - 332

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -